Asahi Kasei Corporation

AHKSY | OTC

Price Alert Chart Builder DCF Calculator

$19.58

-$0.73 (-3.59%)

At close: Nov 5, 2026, 3:58 PM ET

$19.58

$0.00 (0.00%)

After-hours: Nov 5, 2026, 4:01 PM ET

Overview Rating Statistics Financials Earnings Ownership Dividends Profile

-3.59%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 5, 2026

51.8

-0.9 pts

Fundamentals Average

Market Sentiment Neutral

Moat Narrow

Sector Rank #348/881 (Top 40%)

Full Analysis

Key Statistics

Market Data

Market Cap $13.06B

1D Range

19.58 20.54

52W Range

16.00 23.77

Valuation (TTM)

PE 22.03

PB 1.04

EV/EBITDA 6.18

Valuation (NTM)

Forward PE 12.12

Forward PEG 0.44

Price Target $0.00

Cash Flow

FCF Yield 4.1%

SBC Adj. FCF Yield 4.1%

SBC Impact N/A

Margins

Gross Margin 33.5%

Operating Margin 8.2%

FCF Margin 2.8%

Growth (CAGR)

Revenue 3Y | 5Y 5.3% | 7.2%

Dil EPS 3Y | 5Y 49.9% | 11.9%

FCF 3Y | 5Y -33.5% | -2.3%

Returns

ROA 4.3%

ROE 9.5%

ROIC 5.0%

Financial Health

Net Debt

¥739.79B ($4.55B)

Current Ratio 2.01

Interest Coverage 19.20

Dividends

Div Yield 2.71%

Payout Ratio 0.4%

FCF Payout Ratio 64.9%

All Key Statistics

Loading financial charts...

Profile

Asahi Kasei Corporation, a multinational enterprise established in Tokyo, Japan, in 1922, engages globally in the manufacturing, processing, and sale of a diverse array of products across three primar...

Sector Industrials

Industry Conglomerates

Employees 47,895

IPO Date Oct 4, 2007

Website www.asahi-kasei.com

Fiscal Year n/a

Full Company Profile

Latest News

$Asahi Kasei Therapeutics Announces FDA Approval of HOVILPRI® (pritelivir) Tablets for Mucocutaneous HSV Lesions Refractory (With or Without Resistance) to Standard Antiviral Treatment in Immunocompromised Adults$

27 days ago · businesswire.com

Asahi Kasei Therapeutics Announces FDA Approval of HOVILPRI® (pritelivir) Tablets for Mucocutaneous HSV Lesions Refractory (With or Without Resistance) to Standard Antiviral Treatment in Immunocompromised Adults

TOKYO--(BUSINESS WIRE)--Asahi Kasei Therapeutics, Inc., the global specialty pharmaceutical business of Tokyo-based Asahi Kasei, with U.S. and European business headquarters in Cary, North Carolina, today announced that the U.S. Food and Drug Administration (FDA) has approved HOVILPRI® (pritelivir) 100 mg tablets for the treatment of mucocutaneous lesions caused by herpes simplex virus (HSV) infection that is refractory (with or without documented resistance) to treatment with acyclovir, valacy.

27 days ago · reuters.com

US FDA approves Asahi Kasei's drug for persistent herpes infections

The US FDA on Friday approved Japan's Asahi Kasei's drug for persistent herpes simplex virus sores in certain patients with weakened immune systems ‌who have not responded to available antiviral treatments.

28 days ago · businesswire.com

Asahi Kasei Microdevices Holds IEEE Milestone Commemoration Ceremony in Nobeoka for the Commercialization of Thin-Film Hall Elements

TOKYO--(BUSINESS WIRE)--Asahi Kasei Microdevices held a ceremony to celebrate the recognition of the 1983 commercialization of thin-film Hall elements as an IEEE Milestone.

29 days ago · businesswire.com

Asahi Kasei Therapeutics Announces First Patient Dosed in Phase 2a Trial of AIC468 for BK Virus Infection in Kidney Transplant Recipients

TOKYO--(BUSINESS WIRE)--Asahi Kasei Therapeutics announced that the first patient has been dosed in a randomized Phase 2a clinical trial (NCT07503561) evaluating AIC468.

1 month ago · businesswire.com

Asahi Kasei to Integrate Global Pharmaceutical Brand Under Asahi Kasei Therapeutics

TOKYO--(BUSINESS WIRE)--Asahi Kasei Therapeutics, Veloxis Pharmaceuticals, Calliditas Therapeutics, and AiCuris will come together under the Asahi Kasei Therapeutics brand.

2 months ago · businesswire.com

Asahi Kasei Introduces VANTIJ® SU-VFC Benchtop to Improve Efficiency and Consistency in Gene Therapy Manufacturing

GLENVIEW, Ill.--(BUSINESS WIRE)--Asahi Kasei Bioprocess will unveil the VANTIJ® SU-VFC Benchtop at Bioprocess International East (BPI EAST) 2026.

2 months ago · businesswire.com

Asahi Kasei Unveils New Wet-Process Separator Coating Line in North Carolina, Advancing the Company's 40-Year North American Battery Separator Strategy

TOKYO--(BUSINESS WIRE)--Asahi Kasei held a grand opening ceremony for its new Hipore™ wet-process lithium-ion battery separator coating line in Charlotte, North Carolina.

3 months ago · businesswire.com

Asahi Kasei Develops Novel Lithium Pre-doping Technology to Raise Energy Density and Lower Cost of Silicon-rich Lithium-ion Batteries

TOKYO--(BUSINESS WIRE)--Asahi Kasei(TOKYO:3407), a diversified global company, has developed a novel pre-doping technology for high-voltage lithium-ion batteries (LIBs) with silicon-based anodes. This technology enables lithium carbonate to serve as an additional lithium source at lower voltages, reducing the permanent capacity loss that typically occurs in silicon-rich cells during the first charge–discharge cycle. Going forward, Asahi Kasei will work closely with customers worldwide to explor.